Farmacogenómica del Cáncer ; Pharmacogenomic of cancer
Gedelcan
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (7)
2023
-
Correlation Between Endoglin and Malignant Phenotype in Human Melanoma Cells: Analysis of hsa-mir-214 and hsa-mir-370 in Cells and Their Extracellular Vesicles
Advances in experimental medicine and biology, Vol. 1408, pp. 253-272
-
The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease
Nefrologia, Vol. 43, Núm. 2, pp. 245-250
2022
2021
-
Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)
Oncology Letters, Vol. 22, Núm. 5
2011
-
Relación entre concentración intraoperatoria de parathormona y evolución postoperatoria del hiperparatiroidismo primario
Cirugia Espanola, Vol. 89, Núm. 6, pp. 386-391
2009
-
Hormone-sensitive lipase expression and IHC localization in the rat ovary, oviduct and uterus
Journal of Histochemistry and Cytochemistry, Vol. 57, Núm. 1, pp. 51-60
2003
-
Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer
International Journal of Cancer, Vol. 107, Núm. 5, pp. 781-790